



# What if diseases could be detected before presenting clinical symptoms?



## MANAGEMENT

Daniel Skovronsky, MD, PhD  
President and CEO

Richard Baron  
Chief Financial Officer

Alan P. Carpenter Jr., PhD, JD  
Executive Vice President, Business Development,  
Legal and Regulatory Affairs

Christopher J. Bunting  
Vice President, Marketing & Sales

Franz F. Hefti, PhD  
Chief Scientific Officer

Christopher Clark, MD  
Medical Director

Michael Pontecorvo, PhD  
Vice President, Clinical Development

John Lister-James PhD  
Vice President, Chemical  
Development and Manufacturing

Paul Kennedy, PhD  
Vice President, Chemical Development

## BOARD OF DIRECTORS

Daniel Skovronsky, MD, PhD  
President and CEO

William Hamilton, PhD, MBA  
Wharton School, University of Pennsylvania

Ed Hurwitz, J.D., MBA  
Alta Partners

Matthew Rhodes-Kropf, PhD  
Columbia University; RK Ventures

Ernest Mario, Ph.D.  
Capnia, Inc., CEO & President

Gary J. Kurtzman, M.D.  
Safeguard Scientifics, Vice President

## SCIENTIFIC ADVISORS

Hank F. Kung, PhD  
Chairman, SAB  
Professor of Radiology and Pharmacology,  
University of Pennsylvania

Michael Devous, PhD  
Professor of Radiology and Associate  
Director of Nuclear Medicine Center,  
University of Texas, Southwestern

Joanna Fowler, PhD  
Adjunct Professor, Brookhaven National Labs

Masanori Ichise, MD, FRCPC  
Professor of Clinical Radiology at  
Columbia University College of  
Physicians and Surgeons

Michael Kilbourn, PhD  
Professor of Radiology and Director  
of PET Chemistry Section, University  
of Michigan


James Smith, PhD  
Former EVP, Research and Development,  
EPIX

Henry N. Wagner, Jr., MD  
Professor Emeritus, Johns Hopkins University

At Avid, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an industry-leading management team with extensive imaging and CNS drug development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and diabetes. This is possible because our molecular imaging compounds may be able to detect the first stages of pathological change, allowing early treatment and management of people at risk — before symptoms of disease can develop.

Avid has three clinical-stage molecular imaging product development programs supported by extensive IP in the field of molecular brain imaging. Avid has developed proprietary targeting agents to image amyloid plaques and is currently in Phase III clinical trials of AV-45, its best-in-class PET imaging compound for the detection of Alzheimer's disease. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT2) to image pathology in dementia with Lewy bodies (DLB), Parkinson's disease (PD), and has recently started a research project in diabetes mellitus (DM). Avid's lead compound for PET imaging VMAT2, <sup>18</sup>F-AV-133, has completed Phase I trials for the imaging of PD, DLB, and DM. These agents have the potential to revolutionize early diagnosis and monitoring of disease.

## PREVALENCE OF NEURODEGENERATIVE DISEASE IN THE US



Avid's imaging compounds are targeted to more than 80% of the rapidly growing neurodegeneration population. The prevalence of AD alone may soar to 7.7 million people by 2030 and 16 million by the middle of the century.

Sources: Alzheimer's Association, National Parkinson's Foundation, Lewy Body Dementia Association

## CLINICAL PROGRAMS

### AVID'S DEVELOPMENT PIPELINE

Avid is a leader in the development of AD imaging agents and has multiple promising PET and SPECT compounds in clinical trials. Its second generation amyloid plaque PET imaging compound, AV-45, is now being extensively studied in Phase III clinical trials following recommendations from a recent FDA Advisory committee on the development of amyloid imaging tracers. Avid is also working with multiple global pharmaceutical partners in using Avid's innovative biomarker technology to assist in finding new generation drugs for Alzheimer's disease. Avid has a pipeline of research leads through its continued collaborations with the University of Pennsylvania and other major academic research institutions.

### Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI)

Early intervention with the four approved drugs commonly used to treat AD results in qualitative and quantitative patient improvements. However, differential diagnosis of patients with Alzheimer's is challenging, and misdiagnosis can lead to inappropriate treatment and management of patients with cognitive impairment. Patients with very early disease, not yet consistent with AD, are particularly difficult to diagnose since not all patients with Mild Cognitive Impairment (MCI) progress to AD. New treatment methods for slowing or reversing the deposition of insoluble amyloid in AD patients' brains are the subject of intensive clinical research. Avid's  $\beta$ -amyloid imaging agent AV-45, is now being studied as a biomarker for the identification of patients who may have the best chance of responding to these new treatments.

### Parkinson's disease (PD)

PD is diagnosed by clinical criteria, which can be inaccurate, particularly early in the disease course. Definitive diagnosis of PD currently requires verification of degeneration of dopaminergic neurons in the brain at autopsy. Avid's VMAT2 development compound AV-133 will allow *in vivo* imaging of dopaminergic degeneration and may facilitate early diagnosis and monitoring of PD patients.

### Dementia with Lewy bodies (DLB)

DLB symptoms (progressive cognitive decline combined with variations in alertness and attention, hallucinations, and Parkinson-like motor symptoms) are caused by the build-up of Lewy bodies composed of the alpha-synuclein protein, which accumulates inside neurons in memory and motor-control areas of the brain. Lewy bodies can also be found in the brains of people with Parkinson's and Alzheimer's diseases, suggesting that DLB is related to these and that an individual can have both amyloid and alpha-synuclein based dementias. Imaging agents such as AV-133, now in Phase I development, may allow the differential diagnosis of DLB from AD and lead to the selection of appropriate therapeutics.

### Diabetes mellitus (DM)

Type 1 and Type 2 diabetes affect 21 million people in the U.S. alone. Diabetes results from an imbalance between insulin production and metabolic demand, leading to uncontrolled blood glucose levels and to illnesses including heart and kidney failure. The loss of the insulin-producing beta cells of the pancreas is at the core of diabetes. Avid's AV-133 for PET imaging may allow the *in vivo* imaging of beta cells and provide an earlier signal of a pre-diabetic state than current diagnostic methods.

## INTELLECTUAL PROPERTY

Avid has exclusive worldwide licenses to several patents and patent applications covering AD imaging compounds from the University of Pennsylvania, and it has an exclusive license to the IP covering the Parkinson's and Lewy body imaging compounds from the University of Pennsylvania and the University of Michigan. Avid also has rights to IP from Columbia University for imaging diabetes as well as rights to a pipeline of radiopharmaceuticals for other indications under investigation through sponsored research agreements with the University of Pennsylvania.

## INVESTORS

Avid's investors include AllianceBernstein, Alta Partners, Safeguard Scientifics, Pfizer Strategic Investment Group, Lilly Ventures, RK Ventures and BioAdvance. Avid closed a \$34.5M funding round in May 2009.